American Society of Nephrology (ASN) Kidney Week 2021

Methylprednisolone improves major kidney outcomes in patients with IgAN

Elaine Soliven, 20211126000000

Treatment with methylprednisolone reduces the risk of kidney composite outcomes, including kidney failure, 40 percent decline in eGFR, or death due to kidney disease, in patients with IgA nephropathy (IgAN), according to the TESTING* study presented at ASN Kidney Week 2021.

Lumasiran reduces plasma oxalate in advanced PH1

Elvira Manzano, 20211125000000

Treatment with the RNAi therapeutic lumasiran led to a significant reduction in plasma oxalate and pre-dialysis oxalate levels in patients with advanced primary hyperoxaluria type 1 (PH1), according to the 6-month primary analysis of phase III ILLUMINATE-C trial presented at ASN Kidney Week 2021.

Oral daprodustat on par with ESA for anaemia in CKD

Oral daprodustat: A ‘transformative’ care for anaemia in CKD?

Pearl Toh, 20211124140100

The oral HIF-PHI* daprodustat was noninferior to standard treatment with erythropoiesis-stimulating agents (ESAs) for increasing haemoglobin levels to within target range, without increasing cardiovascular (CV) risk in patients with anaemia due to chronic kidney disease (CKD), regardless of whether they were dialysis dependent or not, according to the phase III ASCEND-D/-ND trials presented at ASN 2021.

AKI post-AMI tied to more serious kidney outcomes

Roshini Claire Anthony, 20211119180001

Patients who develop acute kidney injury (AKI) following an acute myocardial infarction (AMI) have an elevated risk of more serious kidney outcomes including persistent reductions in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), or renal death, according to results of the PARADISE-MI trial.

Dapagliflozin in COVID-19: Outcomes consistent regardless of kidney status

Roshini Claire Anthony, 20211117180001

Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use

Audrey Abella, 20211117100000

In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who were receiving the novel nonsteroidal MRA* finerenone, use of SGLT-2is** at baseline did not influence treatment outcomes, according to a subgroup analysis of the FIDELITY*** trial presented at ASN 2021.

Belimumab benefit sustained regardless of lupus nephritis status

Audrey Abella, 20211115064020

The recombinant human IgG-1λ monoclonal antibody belimumab improved renal outcomes in patients with relapsed and newly diagnosed* active lupus nephritis (LN), according to subgroup analysis results of the BLISS-LN** trial presented at ASN 2021.

Diuretic, too, lowers BP in advanced kidney disease

Pearl Toh, 20211111140100

The thiazide diuretic chlorthalidone significantly reduces systolic blood pressure (SBP) by an average of 10 mm Hg in patients with refractory hypertension and advanced chronic kidney disease (CKD), reveals the CLICK* study presented at ASN 2021 — thus debunking the conventional belief that thiazide diuretics do not work in patients with advanced CKD.